Ripretinib (Mechanism of Action)

In this article, we will discuss Ripretinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.

Pharmacodynamics

Exposure-Response Relationships
Ripretinib exposure-response relationships and the time course of pharmacodynamics have not been fully characterized.

Cardiac Electrophysiology

No large mean increase in QTc interval (i.e. >20 ms) was detected following treatment with Ripretinib at the recommended dose of 150 mg taken orally once daily.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.